NHS England says biosimilar savings, which form a key element of its Medicines Value Programme, have already reached £210 million for 2018/19 and it has asked trusts and CCGs not to sign any new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback